Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

详细信息查看全文

作者：Claire F. Friedman ; Michael A. Postow
关键词：Immunotherapy ; Checkpoint blockade ; Ipilimumab ; Nivolumab ; Pembrolizumab ; Biomarkers ; PD ; 1 ; PD ; L1 ; CTLA ; 4 ; Neoantigens ; Melanoma
刊名：Current Oncology Reports
出版年：2016
出版时间：April 2016
年：2016
卷：18
期：4
全文大小：287 KB
参考文献：1.Robert C et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.CrossRef PubMed
2.Robert C et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17.CrossRef PubMed
3.Robert C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.CrossRef PubMed
4.Wolchok JD et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64.CrossRef PubMed
5.Garon EB et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.CrossRef PubMed
6.Gettinger SN et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–12.CrossRef PubMed
7.Motzer RJ et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–7.CrossRef PubMed
8.Le DT et al. PD-1 blockade in tumors with mismatch repair deficiency. ASCO Meet Abstr. 2015;33(15_suppl):LBA100.
9.Templeton AJ, Templeton AJ, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.CrossRef PubMed
10.Zaragoza J, et al. Neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol. 2015.
11.Ferrucci PF et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer. 2015;112(12):1904–10.CrossRef PubMed
12.Simeone E et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother. 2014;63(7):675–83.CrossRef PubMed
13.Ku GY et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting. Cancer. 2010;116(7):1767–75.CrossRef PubMed PubMedCentral
14.Postow MA, et al. Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma. ASCO Meeting Abstracts, 2013. 31(15_suppl):9052.
15.Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):97–106.CrossRef PubMed PubMedCentral
16.Callahan MK et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. ASCO Meet Abstr. 2013;31(15_suppl):3003.
17.Gaba L et al. Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma. ASCO Meet Abstr. 2015;33(15_suppl):9069.
18.Kim DW et al. Predictive markers for programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis blockade therapy in patients with metastatic melanoma (MM). ASCO Meet Abstr. 2015;33(15_suppl):e20029.
19.Valpione S et al. Personalised medicine: development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. Eur J Cancer. 2015;51(14):2086–94.CrossRef PubMed
20.Gnjatic S et al. NY‐ESO‐1: review of an immunogenic tumor antigen. In: Advances in Cancer Research. Academic Press; 2006. p. 1–30.
21.Yuan J et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A. 2008;105(51):20410–5.CrossRef PubMed PubMedCentral
22.Yuan J et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A. 2011;108(40):16723–8.CrossRef PubMed PubMedCentral
23.Goff SLMD et al. No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma. J Immunother. 2009;32(8):884–5.CrossRef PubMed
24.Weide B et al. Functional T cells targeting NY-ESO-1 or Melan-a Are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol. 2012;30(15):1835–41.CrossRef PubMed
25.Hutloff A et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999;397(6716):263–6.CrossRef PubMed
26.Liakou CI et al. CTLA-4 blockade increases IFNγ-producing CD4 + ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008;105(39):14987–92.CrossRef PubMed PubMedCentral
27.Carthon BC et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a Presurgical clinical trial. Clin Cancer Res. 2010;16(10):2861–71.CrossRef PubMed PubMedCentral
28.Ng Tang D et al. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res. 2013;1(4):229–34.CrossRef PubMed
29.Postow M et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab. J Transl Med. 2014;12 Suppl 1:O8.CrossRef PubMedCentral
30.Robert L et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014;20(9):2424–32.CrossRef PubMed PubMedCentral
31.Cha E et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014;6(238):238ra70.CrossRef PubMed PubMedCentral
32.Postow MA et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. J Immunother Cancer. 2015;3:23.CrossRef PubMed PubMedCentral
33.Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–74.CrossRef PubMed PubMedCentral
34.Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–68.CrossRef PubMed PubMedCentral
35.Filipazzi P et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25(18):2546–53.CrossRef PubMed
36.Tarhini AA et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014;9(2):e87705.CrossRef PubMed PubMedCentral
37.Meyer C et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 2014;63(3):247–57.CrossRef PubMed
38.Callahan M et al. Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. J ImmunoTher Cancer. 2013;1 Suppl 1:O6.CrossRef PubMedCentral
39.Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.CrossRef PubMed PubMedCentral
40.Grosso J et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). ASCO Meet Abstr. 2013;31(15_suppl):3016.
41.••

Herbst RS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7. This was the first paper to examine the role of PD-1/PD-L1 as a potential biomarker of response to PD-1 blockade.CrossRef PubMed
42.Postow MA et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.CrossRef PubMed
43.Wolchok JD et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33.CrossRef PubMed
44.Larkin J, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015.
45.Madore J et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015;28(3):245–53.CrossRef PubMed
46.••

Tumeh PC et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71. Tumeh and colleagues elegantly characterize the tumor immune microenvironment and relationship between tumor infiltrating lymphocytes and response to immunotherapy.CrossRef PubMed PubMedCentral
47.Ji RR et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. 2012;61(7):1019–31.CrossRef PubMed
48.Hamid O et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204.CrossRef PubMed PubMedCentral
49.Ribas A et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. ASCO Meet Abstr. 2015;33(15_suppl):3001.
50.Alexandrov LB et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.CrossRef PubMed PubMedCentral
51.van Rooij N et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31(32):e439–42.CrossRef PubMed
52.••

Snyder A et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–99. This is a seminal paper which establishes the role of mutational load in predicting response to immunotherapy, as well as the potential homology between neoepitopes and viral and bacterial antigens.CrossRef PubMed PubMedCentral
53.Rizvi NA et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.CrossRef PubMed
54.Weber JS et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311–8.CrossRef PubMed PubMedCentral
55.Antonia SJ et al. P2.11-035 Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients treated with non-small cell lung cancer (NSCLC) treated with nivoluamb (Anti-PD-1; BMS-936558; ONO-4538). J Thorac Oncol. 2013;8:S1–S1410.
56.Daud AI. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): correlation of tumor PD-L1 expression with outcome [abstract]. Proc. Ann. Meeting AACR, 2014: p. CT104.
57.Gandhi L. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): antitumor activity and association with tumor PD-L1 expression [abstract]. Proc. Ann. Meeting AACR, 2014: p. CT105.
58.Seiwert TY et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. ASCO Meet Abstr. 2014;32(15_suppl):6011.
59.Ribas A et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). ASCO Meet Abstr. 2014;32(15_suppl):LBA9000.
60.Hamid O et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). ASCO Meet Abstr. 2013;31(15_suppl):9010.
61.Soria JC et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): Additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur J Cancer. 2013;49:S97–S153.CrossRef
62.Powles T et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62.CrossRef PubMed
63.Segal NH et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. ASCO Meet Abstr. 2014;32(15_suppl):3002.
64.Rizvi NA et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2015;33(15_suppl):8032.
65.Segal NH et al. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. ASCO Meet Abstr. 2015;33(15_suppl):3011.

作者单位：Claire F. Friedman (1)
Michael A. Postow (1)

1. Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA

刊物主题：Oncology;

出版者：Springer US

ISSN：1534-6269